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Objective:  
 
To consider the benefits and risks of large
postmarketing outcomes studies, as demonstrated by
studies of the statin drugs.
 
Methods: 
 
Literature review.
 
Results: 
 
The risks were that the statin studies had a
strong coat-tail effect. Each new study was beneficial to
all statins as well as the one studied. Economic analyses
based on the results of the postmarketing studies con-
cluded that the drugs were not cost-effective. Long-term
postmarketing studies were slow to be put into perspec-
tive and did not immediately influence other researchers
or clinicians. During that time, the sponsoring companies
shouldered opportunity costs as well as the actual costs
of the studies. The risk that one drug company would use
another company’s results instead of investing in their
own research did not materialize. The benefits were that
the studies definitively showed that the drugs and the
lowering of lipids were safe and efficacious. The studies
also expanded the indications for the drugs, generated
goodwill in the medical and research communities for
the sponsors, allowed sponsors to include specific
claims in their advertisements, generated follow-up
studies, spawned economic analyses that sparked inter-
est in the medical and lay press, and had a major impact
on clinicians’ use of the drug.
 
Conclusion: 
 
The risks and benefits of postmarketing
studies may depend on the company’s time perspective.
In the short term, the risks may outweigh the benefits.
Only companies that have a longer perspective may find
it beneficial to undertake large postmarketing studies.
 
Introduction
 
Most postmarketing studies are conducted for a
number of strategic reasons: (1) to dispel doubts
about drug side-effects; (2) to reassure providers
and patients about long-term safety; (3) to broaden
indications for use; (4) to define and expand the
target population in whom the drug is used; (5) to
designate the subpopulations for whom it is partic-
ularly effective; and (6) to demonstrate the eco-
nomic efficiency of prescribing the drug. These stud-
ies are expensive because they often require large
numbers of subjects and a long follow-up.
This paper will assess current trends in post-
marketing studies research and address several key
aspects of these studies:
• What types of studies have been implemented?
• What were the risks inherent in these undertak-
ings?
• What were the potential benefits?
• Did the studies affect the drug’s sales?
Given their rich research background, the enor-
mous current interest, the large potential market,
and the continued involvement by many prominent
investigators, we selected the HMG-CoA reductase
inhibitors, or statins, as the focus of our review.
 
Background
 
In the 1980s, it was established that lowering ele-
vated cholesterol could prevent coronary artery
disease [1–6]. Clinical trials in the last 10 years
showed that statins are as effective as previous
lipid lowering drugs in lowering total cholesterol
and LDL while raising HDL [7,8]. They are also
better tolerated and have higher compliance rates
[9–11]. The price of these drugs, however, is also
higher. To justify the use of statins, several post-
marketing studies were conducted (and several
others are ongoing or planned) (Tables 1 and 2).
 
Methods
 
Medline searches were conducted for papers pub-
lished between 1986 and 1997 using the keywords:
cholesterol, cholesterol lowering, cholesterol reduc-
tion, lipid, lipid lowering, hypercholesterolemia, hy-
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droxy methylglutaryl inhibitors, statins, PLAC,
EXCEL, CARE, WOSCOPS, LIPID, ALLHAT,
ADMIT, GISSI, HIT, BIP, Scandinavian, UK heart
protection study, and Oxford trials. Over 180 arti-
cles were identified as relevant to the inquiry and
over 100 were reviewed in depth.
Databases and the Internet were also searched
for references to the studies in the media. Between
1986 and 1997, 544 articles were identified and
45 were reviewed in detail. In addition, 21 news-
paper and magazine files were reviewed.
Sales figures for the different drugs between
1990 and 1997 were obtained from IMS Health.
 
Results
 
Types of Studies
 
In the 1990s, small postmarketing studies with
fewer than 1000 subjects were conducted along
with larger trials. The studies complimented each
other and drew a more complete picture of the
conditions in which statins are effective.
Almost all the direct data-gathering studies
were randomized controlled trials. Exceptions were
pooled studies, one open label study, and a ran-
domized controlled trial that was followed by an
open label extension. Separate economic analyses
were carried out directly on three of these studies.
Over a third of the studies used angiography to
study progression and regression of coronary artery
disease. All but one found that after 6 months of
treatment, the statins aided regression.
 
Strategic Risks
 
Postmarketing studies are accompanied by risks
that careful design and focused objectives may not
eliminate.
 
Negative Results.
 
One of the most basic risks of a
postmarketing study is that it will fail to confirm,
or even negate, the company’s earlier claims for the
drug. This was not the case for the statins. In all 16
of the large, randomized, placebo-controlled trials
(RCT) that used monotherapy and included mea-
sures of mortality or stroke, the statins lowered to-
tal cholesterol and LDL [12]. In fact, two ongoing
RCTs, GISSI-P and LIPID, canceled their placebo
arms early because of ethical considerations. The
only postmarketing study that showed no differ-
ence with treatment was the Lovastatin Restenosis
Trial [13].
 
Coat-Tail Effect.
 
The risk that a postmarketing
study might support the claims of all drugs in its
class, not just the particular drug studied, proved
very real for the statins. Other pharmaceutical firms
reaped the benefits of the sponsor’s investment.
When the media reported findings from landmark
trials such as WOSCOPS, newspapers and maga-
zines tended to mention the statins as a class or list
all the statin drugs currently on the market [14].
A search for articles in selected newspapers that
mentioned the individual statin drugs found that
statins were often discussed as a group. (Fig. 1).
Lovastatin/Mevacor, the first statin to be regis-
tered and the only one on the market for over two
years, was named in 437 articles between 1986 and
1997. Over a third of these articles also mentioned
other statins. Drugs more recently approved by the
FDA were likely to be classed with other statins.
Pravastatin/Pravachol, registered in 1991, was named
in 157 articles. Other statins were also mentioned
in 132 of these articles. Atorvastatin/Lipitor ap-
peared in 39 articles, 25 of which mentioned other
statins.
The media are not alone in grouping the statins
together. A similar phenomenon is seen in the
peer-reviewed literature. One investigator extrap-
olated the findings of the 4S study of simvastatin
to calculate hospitalization, revascularization, and
total hospital days associated with all four statins
on the market and concluded that fluvastatin pro-
vided the most cost-effective therapy [9].
Postmarketing studies of one statin may have
helped increase sales of all statins. The results of a
large postmarketing study of lovastatin (EXCEL)
were published in 1991. Pravastatin and simvasta-
tin were registered at the end of that year. In
March 1992, 87% of 1.18 million new statin pre-
scriptions were for lovastatin. By December 1992,
although no new postmarketing studies had been
published, new prescriptions had increased to
1.36 million, and pravastatin and simvastatin had
captured a third of the market. By December
1994, postmarketing studies had been published
for pravastatin and simvastatin, including two
studies with over 1000 subjects, and new prescrip-
tions, including those for the more recently regis-
tered fluvastatin, rose to over 8 million. Despite
the many postmarketing studies for the newer st-
atins, lovastatin retained almost 50% of new pre-
scriptions.
While publication of postmarketing studies for
any one of the statins increased public exposure for
all of them, competitors did not abandon their own
postmarketing studies. All pharmaceutical firms
with registered statin drugs are currently conducting
or planning their own large-scale trials. Table 1 lists
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completed and soon to be completed postmarketing
studies and Table 2 lists ongoing and planned stud-
ies. The manufacturer of atorvastatin, a recently
registered lipid-lowering HMG CoA reductase in-
hibitor, is sponsoring four postmarketing studies
that are scheduled to conclude between 1998 and
2001, and include an expected total of 5750 partici-
pating patients (Table 2).
 
Insufficient Value for Money.
 
Despite a success-
ful clinical outcome, an economic analysis may
lead to the conclusion that the drug is not cost-effec-
tive. One analysis used data from EXCEL to show
that lovastatin is not cost-effective except when used
for specific groups, such as high risk men, and that
the cost per life-year saved (LYS) was greater than
for other primary CHD interventions [1]. Another
analysis found that lovastatin at 20 mg/day was
cost effective (
 

 
$US 50,000/LYS) in hypertensive
males aged between 24 and 45 years, in selected
high risk males aged 35 to 44, and in hypertensive,
obese females aged 55 to 74 who smoked [15]. A
United Kingdom (UK) study used results from the
4S simvastatin study to show that treatment for all
those who might benefit was not possible, given the
resources of the British National Health Service
(NHS) [16]. Another analysis used 4S study data to
show cost-effectiveness for specific age-limited pop-
ulations [17].
 
Long in the Tooth.
 
Most postmarketing studies
require extensive follow-up of patients and take
many years to complete, by which time the results
and conclusions may seem stale or irrelevant. While
ongoing postmarketing studies of statin drugs con-
tinue to be relevant, this may not always be the
case for other therapies. Even lipid lowering drugs
may not evoke as much interest in the future. At-
tention may shift to prevention activities such as
lowering homocysteine [18].
Figure 1 Number of articles about each statin drug by itself and in combination with other statins in selected magazines and
newspapers (1986–1997). Selected newspapers: Wall Street Journal, Chicago Tribune, China Daily, The Daily Yomiuri, Financial
Times, The Guardian, Japan Economic Newswire, Los Angeles Times, New York Times, The Nikkei Weekly, The Observer,
The South China Morning Post, The Times, The Washington Post, Le Monde, El Nacional. Selected Magazines: Business Week,
Fortune, Newsweek, Time, US News & World Report.
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Weak Influence.
 
It may take a long time for the
results of postmarketing studies to influence prac-
titioners. For several years after the definitive find-
ings of 4S and WOSCOPS were published, many
of the issues surrounding lipid lowering drugs
continued to circulate in journals and on the Inter-
net. This may have been due to the appearance of
papers scheduled for publication before the results
of the postmarketing studies were available. For
example, a meta-analysis published in December
1994 did not include the 4S data published in No-
vember 1994 [19].
Another article barely considered the results of
WOSCOPS, announced and published six weeks
before, mentioning it only in an addendum and
dismissing the 5-year follow-up as too short. The
editorial [20] also questioned the long-term safety
of the statins. In discussions of the editorial in two
major newspapers [21,22], one mentioned the
WOSCOPS results in a short paragraph buried in
the middle of the article, while the other discussed
neither the WOSCOPS results nor their relevance
to the opinions expressed in the editorial.
A summary of a 1993 article accessed from a
Web site on July 24, 1997 [23] concluded that be-
cause of cost, initial use of niacin made most sense
for patients with mild hypercholesterolemia. Al-
though this summary was on the web in mid-1997,
the summary did not update the 1993 article by re-
ferring to any of the postmarketing studies pub-
lished since then.
Prior to publication of postmarketing study re-
sults, information from smaller clinical trials is of-
ten pooled to generate estimates [24]. Although
these analyses should be superseded by the post-
marketing study, they may remain influential and
later analysts may continue to use their estimates
rather than those of the postmarketing study.
It takes time for a large postmarketing study to
influence clinical practice. Sometimes multiple
smaller studies continue to influence practice for
years, for example, the publication of landmark
studies such as 4S (simvastatin, 1994), WOSCOPS
(pravastatin, 1995) and CARE (pravastatin, 1996)
were not immediately reflected by new prescrip-
tions. In the first quarter of 1996, lovastatin still
had 35% of the dollar total, simvastatin 36% and
pravastatin 20%. It was not until the first quarter
of 1997 that lovastatin had dropped to 24%, sim-
vastatin rose to 43%, and pravastatin rose to 24%.
 
Opportunity Costs.
 
Once a pharmaceutical firm
commits to a postmarketing study, particularly a
large, long-term one, resources are dedicated to
that purpose and cannot be easily applied to any-
thing else. Even a 1-year follow-up study requires
more than a year to plan and carry out, and many
of the newer postmarketing studies have follow-
ups of 5 years or more. From planning to publica-
tion, the time commitment for such a study may
be close to 10 years. During this time, financial
and human resources that are devoted to the
project cannot easily be reassigned to other
projects or lines of investigation.
In addition, when a company has committed to
a postmarketing study, the scientific community
makes it very difficult to cancel because of ensuing
negative perceptions. The effect on personnel of
developing a project and not carrying it to com-
pletion must also be considered.
 
Strategic Benefits
 
Safety Concerns.
 
A well-planned postmarketing
study can definitively address serious safety con-
cerns. The 4S, CARE, and particularly WOSCOPS
studies showed that in spite of findings from the
meta-analyses and literature reviews conducted in
the 1980s and early 1990s, lowering cholesterol did
not increase all-cause mortality; in fact, the oppo-
site occurred [25].
In addition, postmarketing studies published in
1994 and 1995 which examined plaque regression
showed that lowering cholesterol levels could not
only slow the progressive damage to the coronary
arteries but also promote regression of coronary
atherosclerosis [26–29]. Other postmarketing stud-
ies found a correlation between active statin treat-
ment and a significant reduction in fatal events in
patients with carotid artery stenosis [30,31]. Inves-
tigators also found that treatment led to a signifi-
cant reduction in stroke [27], a finding confirmed
by a recent meta-analysis [32].
 
New Indications.
 
Postmarketing studies can sug-
gest new indications for a drug and change the di-
rection of ongoing studies. WOSCOPS opened up
primary prevention, a huge potential new market.
Following the 1994 publication of the 4S study, a
principal investigator in the LIPID study argued
for continuing follow-up [33] and expansion of
that study’s objectives to include stroke. That the
investigator thought it necessary to write the arti-
cle, and that a respected, peer-reviewed journal
felt the topic warranted the article’s prompt publi-
cation testifies to the importance of the earlier
postmarketing studies. LIPID was stopped in 1997
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when a difference in mortality of 3 standard devi-
ations (SD) was detected [34].
 
Goodwill.
 
Major postmarketing studies can bol-
ster the reputation of sponsoring pharmaceutical
firms as leaders in the field. Principal investigators
are often invited to speak at conferences, sympo-
siums, and workshops, keeping drug awareness
high in the medical community and increasing
comfort with the drug. A large postmarketing
study will give the pharmaceutical company credi-
bility in sponsoring some of these conferences,
and press coverage of these meetings may produce
articles in newspapers and magazines. Investiga-
tors and others associated with the drug will be
considered “players in the field” and may be in-
vited to take part in special workshops or consen-
sus committees to determine practice guidelines.
Publication of large postmarketing studies may
help newer drugs compete with long-standing,
well-studied drugs. Lovastatin, for example, was
approved almost 3 years before pravastatin and
simvastatin, and had been the subject of many re-
search articles prior to publication of the 4S and
WOSCOPS results. Nevertheless, the scientific and
clinical excitement surrounding announcement of
the pravastatin and simvastatin results balanced
lovastatin’s long string of articles.
 
Halo Effect.
 
The credibility gained from a well-
conducted postmarketing study may positively in-
fluence both the sponsor’s future drug validation
studies and the scientific reputation of the research-
ers within the firm.
 
Advertisements.
 
A sufficiently persuasive post-
marketing study may allow a company to make
more specific claims about a drug. Because of the
WOSCOPS study, the FDA gave the manufacturer
the right to claim that pravastatin prevented first
myocardial infarctions. A 1997 advertisement for
pravastatin in a leading medical journal promi-
nently used that claim. Advertisements for simvas-
tatin and atorvastatin cannot make the same
claim. A simvastatin advertisement, using findings
from 4S, claims that the drug is “the only statin
clinically proven to save lives of patients with
CHD and high cholesterol.” The atorvastatin ad-
vertisement is several pages longer than those of
simvastatin and pravastatin, perhaps reflecting the
need to counterbalance physicians’ familiarity
with the older statins and the weight of previous
postmarketing studies.
 
Economic Analyses.
 
The large postmarketing stud-
ies of the statins were accompanied by economic
analyses that generated additional interest and de-
bate in the lay press. A study of the cost-effective-
ness of lovastatin in prevention of CHD was pub-
lished in 1995 [1] based on the results of the 1991
EXCEL postmarketing study. The cost-effective-
ness of simvastatin was addressed in studies pub-
lished in 1996 [16,35] and 1997 [17] based on the
results of the 1994 4S study. Economic analyses of
pravastatin based on the 1995 WOSCOPS study
were published in 1998 [36]. A review of the indi-
vidual economic analyses of the statins was pub-
lished even later and confirmed the cost-effective-
ness of the statins in reducing coronary artery
disease (CAD). The review singled out statins that
had been the focus of large postmarketing studies:
simvastatin and the 4S trial for secondary preven-
tion, lovastatin and the AFCAPS/TexCAPS trial
for primary prevention, and pravastatin and the
WOSCOPS, CARE, and LIPID trials for primary
and secondary prevention [15].
 
Sequels.
 
After the initial economic analyses using
data generated by a postmarketing study, smaller
trials, or large follow-up trials, allow a pharmaceu-
tical company to maintain momentum. As results
of the 4S trial were announced, the HPS study was
launched, an even larger comparison of simvastatin
with placebo and vitamins A, E, and beta-carotene.
This 20,000 patient study is not scheduled to finish
until 1999 (Table 2). A year before WOSCOPS re-
sults were announced, pravastatin became part of a
large primary prevention trial of antihypertensive
medication, ALLHAT, which is not due to be com-
pleted until 2002 or 2004.
Postmarketing studies can also be seen as se-
quels to earlier work. An editorial in 
 
Lancet
 
 after
WOSCOPS was published [37] pointed out that
the Los Angeles Veterans Diet Trial, the World
Health Organization (WHO) Clofibrate Trial, the
Lipid Research Clinics Cholestyramine Trial, and
the Helsinki Heart Trial with gemfibrozil all reached
the same conclusion as WOSCOPS: healthy men
at high risk for coronary heart disease benefit
from reducing their hypercholesterolaemia.
Research stemming from landmark studies takes
longer to appear in the literature. A review of arti-
cles bears this out; this review included the 
 
Ameri-
can Heart Journal, American Journal of Cardiol-
ogy
 
, the 
 
Journal of the American College of
Cardiology
 
, the American Journal of Hypertension,
the European Heart Journal during 1995 to 96,
and abstracts from the 17th and 18th Congress of
the European Society of Cardiology. While there
were 15 references to lovastatin, 25 to pravastatin,
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16 to simvastatin, and 29 to fluvastatin, only six re-
ferred to other postmarketing studies. Two referred
to REGRESS, three to 4S, and one to MAAS.
Influence on Pooled Results. In the planned-pooled
postmarketing studies, the larger studies such as
WOSCOPS, CARE, and 4S carry more weight than
smaller studies with fewer than 500 patients. When
researchers from academia and others who are not
directly involved in these studies perform meta-anal-
yses on relevant topics, postmarketing studies will
significantly influence the results. For instance, the
meta-analysis of statins and stroke [32] used
WOSCOPS, KAPS, PMSGCRP, PLAC I, PLAC II,
REGRESS, CARE, MARS, CCAIT, 4S, and MAAS.
These studies disproved earlier analyses implicating
lipid-lowering drugs in increased incidence of
stroke.
Dissemination in the Media. Dissemination of the
results in the media (lay press, the Internet, and
nontraditional forms of communication) may
indirectly reach physicians, other health care pro-
viders, and administrators. Figure 1 shows that in-
terest in new drugs such as the statins is high in
the media and that publication of postmarketing
studies provoked such interest. Articles on the
Web and reports on television and radio also re-
flect public interest.
Sales
Figure 2 displays the time of publication of post-
marketing studies and Fig. 3 and 4 show sales and
prescription data from IMS Health. As the number
of studies and the areas examined increased, dollar
total sales and new prescriptions for all the statins
increased. This appears to be the coat-tail effect
(described in the risk section) in operation. How-
ever, there seems to be a time lag between publica-
tion of a postmarketing study and its effect on
sales. The first studies published in the early 1990s
were of lovastatin. Until 1996, lovastatin had the
largest share of the statin market. It was also the
least expensive of the statins until fluvastatin came
on the market in 1994. Both history and price con-
tributed to lovastatin’s position as market leader.
Many postmarketing studies of pravastatin were
published by the middle of the decade, but its share
of the market did not increase dramatically. These
studies may have served, however, to defend the
drug’s share against its less expensive competitors.
On the other hand, 4S appears to have had a dra-
Figure 2 Publication of postmarketing studies.
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matic effect on sales: simvastatin’s share went from
23% at the time of publication to 34% a year later
and to 43% by mid 1997.
The more immediate payoff of 4S to its spon-
sors may be due to the nature of the study popula-
tion. The study included patients who had already
experienced an MI or angina pectoris and were at
high risk for secondary coronary events. Under
these circumstances, cost considerations and possi-
ble side-effects [38] may not be as relevant as a
30% probability of reducing the risk of a coronary
event. This line of reasoning is supported by the in-
crease in simvastatin’s sales within a year of publi-
cation of the 4S study and by subsequent economic
analyses. WOSCOPS, on the other hand, examined
asymptomatic individuals. While pravastatin low-
ered the relative risk of a coronary event, absolute
risk reduction was not great. In such populations,
clinicians may be more likely to wait for subse-
quent and economic analyses before prescribing
the drug in large numbers. Unless pharmaceutical
companies have plans to counter the resistance,
large amounts of money are unlikely to be spent on
asymptomatic individuals. Additional research on
different drug classes needs to be conducted to
confirm this analysis and expand its applicability
to drugs other than the statins.
Discussion
Most of the potential risks associated with conduct-
ing postmarketing studies were demonstrated by the
statin drugs. Not only did these studies exhibit a
strong coat-tail effect, but economic analyses after
some of the studies concluded that use of the drugs
was not cost-effective. Many of the studies took a
long time to complete and even longer for the results
to be influential. In many cases, researchers needed
to conduct secondary studies to put the results of
the postmarketing study into perspective. During
that time, the sponsoring companies shouldered the
costs of the studies, foregoing other opportunities.
Figure 3 Dollar sales 1991–1996.
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Two of the biggest risks did not materialize. The
studies almost uniformly found the drugs effective,
and publication of the results did not discourage
other companies from conducting their own studies.
The postmarketing studies of the statins achieved
most of the potential benefits of this type of study.
They definitively dispelled safety concerns and
generated goodwill in the medical and research
communities. New indications and claims for the
drugs were realized. Through follow-up investiga-
tions, sequels, and economic analyses, the studies
caught the interest of the biomedical and lay press
and had a major impact on practice. While statin
sales increased following publication of the results
of the postmarketing studies, especially after pub-
lication of the results of such large trials as 4S and
WOSCOPS, the relationship between publication
of postmarketing study results and sales increases
is circumstantial and cannot be proven. Statin use
might have increased over time simply because
physicians became accustomed to the drug.
Significance of the costs, risks and benefits of
postmarketing studies will depend on a company’s
time perspective. For a company with a short time
perspective, the risks may outweigh the benefits.
Only those that have a longer perspective will find
it beneficial to undertake such studies. The present
inquiry only examined risks and benefits in the pe-
riod immediately following the study. Future re-
search should evaluate the costs and benefits of
postmarketing studies over a longer time frame.
In conclusion, postmarketing studies had a ma-
jor impact on the use of statins, determination of
their target populations, and the way in which cli-
nicians and researchers viewed their potential use.
Scientifically, the studies were a success. Their eco-
nomic costs and benefits to the sponsoring compa-
nies were more problematic. If sponsors can afford
Figure 4 Total new prescriptions by year.
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the time and costs associated with postmarketing
studies, the benefits may justify the risks.
This analysis was supported in part by a grant from
Pfizer, Inc.
References
1 Hamilton VH, Racicot F-E, Zowall H, et al. The cost-
effectiveness of HMG-CoA reductase inhibitors to
prevent coronary heart disease, estimating the bene-
fits of increasing HDL-C. JAMA 1995; 273:1032–38.
2 Lipid Research Clinics Program. The Lipid research
clinics coronary primary prevention trial results: I.
Reduction in incidence of coronary heart disease.
JAMA 1984;251:351–64.
3 Lipid Research Clinics Program. The Lipid research
clinics coronary primary prevention trial results: II.
The relationship of reduction in incidence of coro-
nary heart disease to cholesterol lowering. JAMA
1984;251:365–74.
4 The Pravastatin Multinational Study Group for
Cardiac Risk Patients. Effects of pravastatin in pa-
tients with serum total cholesterol levels from 5.2 to
7.8 mmol/liter (200–200 mg/dl) plus two additional
atherosclerotic risk factors. Am J Cardiol 1993;72:
1031–7.
5 Gould AL, Rossouw JE, Santanello NC, et al. Cho-
lesterol reduction yields clinical benefit, a new look
at old data. Circulation 1995;91:2274–82.
6 Manninen MH, Olli E, Frick MH, et al. Lipid alter-
ations and decline in the incidence of coronary
heart disease in the Helsinki Heart Study. JAMA
1988;260:641–51.
7 Chrisp P, Lewis NJW, Milne RJ. Simvastatin, a phar-
macoeconomic evaluation of its cost-effectiveness in
hypercholesterolaemia and prevention of coronary
heart disease. PharmacoEconomics 1992;1:124–45.
8 Furberg CD, Byington RP, Crouse JR, et al. Prava-
statin, lipids, and major coronary events. Am J Car-
diol 1994;73:1133–4.
9 Jacobson TA. Cost-effectiveness of 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG-CoA) Reduc-
tase Inhibitor Therapy in the Managed Care Era.
Am J Cardiol 1996;78:32–41.
10 Andrade SE, Walker AM, Gottlieb LK, et al. Dis-
continuation of antihyperlipidemic drugs—Do rates
reported in clinical trials reflect rates in primary
care settings? N Engl J Med 1995;332:1125–31.
11 Goa KL, Barradell LB, McTavish D. Simvastatin, a
reappraisal of its cost effectiveness in dyslipidaemia
and coronary heart disease. PharmacoEconomics
1997;11:89–110.
12 Hebert PR, Gaziano JM, Chan KS, Hoggs SA, et al.
Cholesterol lowering with statin drugs, risk of
stroke, and total mortality, an overview of random-
ized trials. JAMA 1997;278:313–21.
13 Gilbert SP, Weintraub WS, Talley JD, et al. Costs of
coronary restenosis (Lovastatin Restenosis Trial).
Am J Cardiol 1996;77:196–9.
14 Weber J. The battle of blockbuster heart drugs.
Business Week January 27, 1997:93.
15 Hay JW, Yu WM, Ashraf T. Pharmacoeconomics
of lipid lowering agents for primary and secondary
prevention of coronary artery disease. Pharmaco-
Economics 1999;15:47–74.
16 Pharoah PDP, Hollingworth W. Cost effectiveness
of lowering cholesterol concentration with statins in
patients with and without pre-existing coronary
heart disease: life table method applied to health au-
thority population. BMJ 1996;312:1443–50.
17 Johannesson M, Jönsson B, Kjekshus J, et al. Cost
effectiveness of simvastatin treatment to lower cho-
lesterol levels in patients with coronary heart dis-
ease. N Engl J Med 1997; 336:332–6.
18 Stacey M. The fall and rise of Kilmer McCully. The
New York Times Magazine August 10, 1997:25–9.
19 Furberg CD. Lipid-lowering trials: results and limi-
tations. Am Heart J 1994;128:1304–8.
20 Newman TB, Hulley SB. Carcinogenicity of lipid-
lowering drugs. JAMA 1996;275:55–60.
21 Brody JE. The safety of 2 classes of cholesterol-cut-
ting drugs is debated. New York Times January 3,
1996;sect. C8.
22 Bishop JE. Lengthy use of cholesterol drugs raises
question of cancer risk, 2 scientists say. Wall Street
Journal January 3, 1996;sect. B4.
23 Pharmaceutical Information Associates, Ltd. As-
sessing cholesterol-lowering therapy. Medical Sci-
ences Bulletin 1993;16:3–4. Available at: http://
pharminfo.com/pubs/msb/chol_assess.html.
24 Martens LL, Guibert R. Cost-effectiveness analysis
of lipid-modifying therapy in Canada: comparison of
HMG-CoA reductase inhibitors in the primary pre-
vention of coronary heart disease. Clin Ther 1994;
16:1052–62.
25 Shepherd J, Cobbe SM, Ford I, et al. Prevention of
coronary heart disease with pravastatin in men with
hypercholesterolemia. N Engl J Med 1995;333:
1301–7.
26 MAAS Investigators. Effect of simvastatin on coro-
nary atheroma: the Multicentre Anti-Atheroma
Study (MAAS). Lancet 1994;344:633–8.
27 Sacks FM, Pfeffer MA, Moye LA, et al. The effect
of pravastatin on coronary events after myocardial
infarction in patients with average cholesterol lev-
els. N Engl J Med 1996;335:1001–9.
28 Pitt B, Mancini GBJ, Ellis SG, et al. Pravastatin lim-
itation of atherosclerosis in the coronary arteries
(PLAC I): Reduction in atherosclerosis progression
and clinical events. J Am Coll Cardiol 1995;26:
1133–9.
29 Jukema JW, Bruschke AVG, van Boven AJ, et al. Ef-
fects of lipid lowering by pravastatin on progression
and regression of coronary artery disease in symp-
tomatic men with normal to moderately elevated se-
rum cholesterol levels. The regression growth evalu-
Postmarketing Studies 307
ation statin study (REGRESS). Circulation 1995;91:
2528–40.
30 Crouse JR, Byington RP, Bond MG, et al. Prava-
statin, lipids, and atherosclerosis in the carotid arter-
ies (PLAC-II). Am J Cardiol 1995;75:455–9.
31 Salonen R, Nyyssonen K, Porkkala E, et al. Kuo-
pio atherosclerosis prevention study (KAPS). A
population-based primary preventive trial of the
effect of LDL lowering on atherosclerotic progres-
sion in carotid and femoral arteries. Circulation
1995;92:1758–64.
32 Crouse JR, Byington RP, Hoen HM, et al. Reduc-
tase inhibitor monotherapy and stroke prevention.
Arch Intern Med 1997;157:1305–10.
33 Tonkin AM. Management of the long-term inter-
vention with pravastatin in ischaemic disease (LIPID)
study after the Scandinavian simvastatin survival
study (4S). Am J Cardiol 1995;76:107C–12C.
34 The Long-Term Intervention with Pravastatin Is-
chaemic Disease (LIPID) Study Group. Prevention
of cardiovascular events and death with pravastatin
in patients with coronary heart disease and a broad
range of initial cholesterol levels. N Engl J Med
1998;339:1349–57.
35 Jönsson B, Johannesson M, Kjekshus J, et al. Cost-
effectiveness of cholesterol lowering. European
Heart J 1996;17:1001–7.
36 Caro J, Klittich W, McGuire A, et al. The West of
Scotland Coronary Prevention Study: economic
benefit analysis of primary prevention with prava-
statin. BMJ 1997;315:1577–82.
37 Oliver MF. Statins prevent coronary heart disease.
Lancet 1995;346:1378–9.
38 Hulley SB, Walsh J, Newman TB. Health policy of
blood cholesterol, time to change directions. Circu-
lation 1992;86:1026–9.
